Toshiba Boosts 3T MR Performance and Workflow with Software Upgrades

Enhancements to Toshiba's Vantage Titan 3T MR Further Benefit Research and Clinical Use

Toshiba Vantage Titan 3T MR
Hardware and software upgrades to Toshiba’s 3T MR systems improve image quality and workflow so those in both the clinical and research settings have access to the highest levels of performance and information to provide the best possible care.
TUSTIN, Calif., May 29, 2015

To meet both clinical and research needs of MR customers, Toshiba America Medical Systems, Inc. has implemented software and hardware upgrades for the Vantage Titan™ 3T MR imaging system. Available both for new Titan 3T MR systems and for existing installations, these upgrades improve image quality and workflow so those in both the clinical and research settings have access to the highest levels of performance and information to provide the best possible care.

The upgrades feature several enhancements:

  • Saturn Gradient: This entirely new gradient design option provides increased performance and image stability for maximum quality.
  • fMRI Enhancements: With Pianissim™ noise reduction technology, Titan 3T MR systems deliver the quietest fMRI in the industry, ensuring a patient-friendly environment.
  • Diffusion Tensor Imaging: With the benefit of the new gradient design and the Pianissimo noise reduction technology, Toshiba delivers outstanding performance in a patient-friendly environment.
  • Isotropic Imaging: Toshiba's mVox 3D isotropic imaging makes high-quality MPR 3D post-processing possible in any plane.
  • Arterial Spin Labeling: Time-SLIP labeling provides improved visualization of cerebral vascular circulation without the use of contrast media.
  • 16-Channel Flex Medium and Large Coils: These multi-purpose coils improve signal-to-noise ratio for better high-resolution imaging of a variety of anatomical regions.
  • Updated M-Power Interface: This user-friendly interface now includes more flexibility in parameters and new sequences to offer operators better control and faster access to crucial information.

"These software enhancements were designed for customers in both the clinical and research space, highlighting image quality without hindering workflow," said Guy Poloni, director, MR Business Unit, Toshiba. "These upgrades make Toshiba a strong contender in the high-end 3T MR market."

Toshiba will showcase these upgrades to the Vantage Titan 3T system at this year's International Society for Magnetic Resonance in Medicine (ISMRM) annual meeting in Toronto, May 30–June 5, 2015 (Booth #601).

Toshiba Introduces New Patient-Friendly PET/CT System

Celesteion Delivers a More Comfortable Patient Experience with the Industry's Largest Bore, Widest Field-of-View and Fastest Imaging

Imaging scanner from Toshiba Medical Research Institute USA
TUSTIN, Calif., June 9, 2014

Oncology departments can now provide their patients with a better PET/CT imaging experience using Toshiba America Medical Systems, Inc.'s all-new Celesteion (pending 510(k) clearance). The versatile system combines high performance PET and CT for all radiation and oncology imaging needs, including tumor detection, treatment evaluation and CT simulation.

As healthcare reform puts a greater emphasis on patient satisfaction, the Celesteion's numerous patient-friendly features are designed for this new landscape. These include:

  • Industry's Largest Bore – 90 cm CT and 88 cm PET bore offers a feeling of openness for patients, and more accurate CT and PET imaging
  • Fast Imaging – For reduced exam times
    • PET – 450 ps time-of-flight resolution
    • CT – 0.5 second rotation with 0.5 mm detectors producing 32 slices
  • Expansive Field-of-View – 70 cm true CT and PET field-of-view and 85 cm CT extended field-of-view
  • CT Dose Reduction – Ensuring that patient safety is not a choice, Celesteion comes standard with Toshiba's most advanced CT dose reduction technology, AIDR 3D, for safer CT imaging, and is also compliant with MITA's XR-29 Smart Dose Standard

"By listening to our customers and understanding their business, we know there is a need for a PET/CT system that puts patients first, and the Celesteion is that solution," said Satrajit Misra, senior director, CT Business Unit, Toshiba. "Accuracy and efficiency are crucial under healthcare reform, and Celesteion is capable of producing high quality images while improving workflow for providers."

Toshiba's Celesteion is being unveiled for the first time at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting, June 7–11, 2014, in St. Louis.

Toshiba Wins a Contract for ITER’s Superconducting Coils

Begins manufacturing at its Keihin Product Operations and Toshiba IHI Power Systems Corporation in Yokohama

ITER and toroidal field coils
TOKYO, May 20, 2014

Toshiba Corporation (Tokyo: 6502) today announced that it has concluded a contract with the Japan Atomic Energy Agency (JAEA) for the manufacture of toroidal field coils for the International Thermonuclear Experimental Reactor (ITER) being constructed in Cadarache, France. Keihin Product Operations and Toshiba IHI Power Systems Corporation will begin manufacturing the coils the end of this month. The ITER facility will have a total of 18 coils and initiate plasma experiments in 2020.

Toshiba has been commissioned to manufacture four toroidal field coils and six containers to hold the coils, and will start deliveries in 2017. Toroidal field coils are used to produce strong magnetic fields that confine the high-temperature plasma necessary for nuclear fusion to occur.

The ITER project aims to demonstrate nuclear fusion as a viable future energy source. The project is funded and run by seven member entities: Japan, the European Union, the United States, Russia, China, South Korea and India. Thermonuclear fusion occurs in high temperature deuterium-tritium plasma at the order of 100 million degrees Centigrade, and the heat produced by the fusion reaction is used to generate electricity. Because the source of nuclear fusion fuel is abundant in nature, thermonuclear fusion, once proven, is expected to become a perpetual source of energy.

Toshiba has long been involved in the research and development of nuclear fusion technology, participating in design activities and supply of equipment. Toshiba has manufactured equipment, such as coils and power supply systems, for the JAEA Naka Fusion Institute's JT-60, the National Institute of Fusion Science's Large Helical Device and for other institutes in Japan and overseas. In March 2014, Toshiba delivered sectors of the vacuum vessel for JT-60SA, a successor to JT-60. Toshiba will continue to leverage its technologies to contribute to the research and development of leading-edge technologies.

Toshiba to Reinforce Healthcare Systems & Services Businesses

TOKYO, Mar. 27, 2014

Toshiba Corporation (Tokyo: 6502) today announced that it will promote acceleration and expansion of its healthcare business by consolidating Toshiba Group's healthcare-related businesses in a new in-house company, the Healthcare Company, that will be established on July 1. As the global population continues to rise and the developed economies continue to see the graying of society, the healthcare market is expected to enjoy continuous growth in coming years. The Healthcare Company will position Toshiba to grow with the market.

The new company will integrate a wide array of know-how and technologies and deploy them to promote business in following key areas: Diagnosis & Treatment, which will explore new generations of diagnostic imaging in addition to current systems; Prevention, which will aim to reduce the risk of disease; and Convalescence & Nursing Care, which will aid people in recovering from disease and injury. On its establishment, the new in-house company will be around 9,000 people scale.

The Healthcare Company will absorb Toshiba's current Healthcare Business Development Division, the carbon iron radiotherapy system currently handled by the Power Systems Company, the Materials & Devices Division's DNA analysis system, and other healthcare businesses from across Toshiba Group.

Toshiba Medical Systems (TMS), which develops and markets diagnostic imaging systems, including computed tomography and magnetic resonance imaging systems, and medical IT systems, will be positioned as a subsidiary of the Healthcare Company. With global experience spanning more than 135 countries, TMSC will contribute a strong customer base and business assets that will support the new company in integrating and aligning its business operations.

In July 2013, Toshiba defined Healthcare as third major pillar of business, alongside Energy and Storage, and in February 2014 the company announced its strategies for the healthcare business and a fiscal year 2015 sales target of 600 billion yen (approx. UD$6 billion). In keeping with this commitment, Toshiba has now decided to unify all of its healthcare businesses into the new in-house company. By promoting "New Concept Innovation," the Healthcare Company will bring together the wide-ranging technologies of Toshiba Group to create unique, innovative products and services, and to reinforce and expand its business via diverse sales channels.

Toshiba Introduces New Healthcare Business Strategy

Hisao Tanaka, President and CEO of Toshiba Corporation, introduces new healthcare business strategy
Hisao Tanaka
President and CEO, Toshiba Corporation
TOKYO, Feb. 25, 2014

Toshiba Corporation (TOKYO: 6502) has introduced the strategy that it will promote to establish its healthcare business as a third main pillar of operations, along with its energy and storage businesses. The core of the strategy is to develop four business areas, prevention, diagnosis and treatment, prognosis and nursing care and health promotion, with the aim of achieving 600 billion yen in sales in fiscal year 2015.

Diagnosis and treatment is an already tried and tested business that includes such diagnostic imaging equipment as computed tomography systems. Toshiba will now cultivate prevention, which includes reducing the risk of ill by monitoring and predicting individual health; prognosis and nursing care, which will offer services that reduce burdens on families and other caregivers, and help patients to continue to live at home; and health promotion, which will seek to develop safer living environments and support for mental and physical health, so as to help people to continue to lead happy lives.

Toshiba will promote the healthcare business globally and combine and integrate diverse, wide-ranging technologies, towards building a society where people lead healthier, happier lives.

Toshiba Installs First Vantage Titan 3T in US

SDMI Uses Advanced MR System for Wider Range of Patient-Friendly Exams

Vantage Titan 3T from Toshiba American Medical Systems, USA
TUSTIN, Calif., April 3, 2012

Steinberg Diagnostic Medical Imaging Center (SDMI) in Las Vegas needed an MR system to perform a range of patient exams at a high-volume imaging center. To solve this issue, it recently installed the first Vantage Titan™ 3T in the U.S. from Toshiba America Medical Systems, Inc. With the Vantage Titan 3T's multi-port transmission technology and quiet gradients, physicians can perform artifact-free body imaging with ease, for improved patient comfort and outcomes.

"Toshiba's Vantage Titan 3T is truly the first patient-friendly 3T on the market," said Dr. Mark Winkler, professor of health sciences at the University of Nevada, Las Vegas and founding partner of SDMI. "We use this robust, all purpose scanner for a variety of exams."

By making 3T MR exams more comfortable, hospitals and imaging centers can greatly improve patient compliance, exam efficiency and productivity. The Vantage Titan 3T's open bore offers a 71 cm aperture and features Toshiba's exclusive PianissimoTM noise-reduction technology, which reduces exam noise by up to 33 dB(A), making the Vantage Titan 3T MR the quietest available. The system is also equipped with multi-port transmission, an advanced radio frequency transmission technology for artifact-free body imaging.

"We designed the Vantage Titan 3T MR with our customers in mind, addressing the need for a patient-friendly system," said Stuart Clarkson, director, MR Business Unit, Toshiba. "Providing clinicians with a diagnostic imaging tool that produces clear images for any exam type not only helps hospitals increase workflow and productivity, but improves diagnostic confidence for better treatment planning."

Article source:

Toshiba’s Hybrid Bi-Plane System

Infinix-i Bi-Plane System to Be Used During Live Clinical Cases at PICS-AICS

Toshiba Infinix-i Biplane Cardiovascular X-ray System from Toshiba American Medical Systems
CHICAGO, April 16, 2012

Performing pediatric cardiovascular interventions requires imaging equipment specifically designed for the setting. With superior access to both patient and equipment, Toshiba America Medical Systems, Inc.'s Infinix-i™ bi-plane cardiovascular X‑ray system will be used during two live pediatric cases at the Pediatric and Adult Interventional Cardiac Symposium (PICS-AICS), April 15–18, 2012, in Chicago.

The live cases will be performed on Tuesday, April 17, 2012, by leading interventional cardiologists:

Rush University Medical Center, Chicago—Ziyad M. Hijazi, M.D., and Zahid Amin, M.D.
Nationwide Children's Hospital, Columbus, Ohio—John P. Cheatham, M.D.

Toshiba's Infinix-i systems feature an industry-leading five-axis positioner, allowing for unrestricted patient access to facilitate advanced, complex procedures with ease. Infinix-i's design, system mechanics and tableside dose reduction features all contribute to faster exam times and safer procedures.

"During pediatric interventions, the Infinix-i moves like a hovercraft, with C-arm movement that enables physicians to obtain difficult-to-reach imaging angles for more efficient diagnoses and treatment," said Stephen Bumb, director, X‑ray Vascular Business Unit, Toshiba. "The PICS-AICS live cases provide real-life clinical examples of how Toshiba's technology improves patient care in the cath lab."